Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/<scp>TAF</scp>) as initial treatment in people with human immunodeficiency virus‐1 (<scp>HIV</scp>‐1): A systematic literature review of clinical and patient‐reported outcomes
Jade Ghosn(Délégation Paris 5), Lili Dai(Affiliated Hospital of Hangzhou Normal University), Aws Al‐Hayani(Hospital Universitario Fundación Jiménez Díaz), Fernando Alvarez Bognar(Gilead Sciences (United States)), David J. Malebranche(Gilead Sciences (United States)), Jeremy Chow(The University of Texas Southwestern Medical Center), Hansel Tookes(University of Miami), Monica Gandhi(University of California, San Francisco), Bhumi Gandhi‐Patel(Gilead Sciences (United States)), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Max Lee(Costello Medical Consulting (United Kingdom))
Cited by 1
Related Papers
Mpox in people with advanced HIV infection: a global case series
|The Lancet|2023|506
Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators
|The Journal of Infectious Diseases|2007|173
Hospital-Acquired Infectious Endocarditis Not Associated with Cardiac Surgery: An Emerging Problem
|Clinical Infectious Diseases|1995|170
The Spectrum of Cardiovascular Infections due to Salmonella enterica
|Medicine|2004|155